Tagraxofusp-erzs

Tagraxofusp-erzs
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Uma Maveli[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete Boxed Warning. There have been fatal and life-threatening cases of Capillary Leak Syndrome Before initiating treatment, check patient to ensure proper cardiac function and that serum albumin is greater than 3.2 g/dL Measure Albumin levels periodically during treatment, and monitor closely after ending treatment for a period of time that is clinically instructed Additionally, assess patients periodically and monitor carefully for signs or symptoms of CLS. Some signs and symptoms include weight gain, edema (new or progressively deteriorating), pulmonary edema, hypotension, orhemodynamic instability

Overview

Tagraxofusp-erzs is a antineoplastic biologic response modulator that is FDA approved for the treatment of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include Some adverse reactions that occur in patients undergoing treatment with Tagraxofusp-erzs are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight gain. Some lab abnormalities that occur include decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose,ALT, and AST..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

ELZONRIS is indicated for:

• ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm
• It is a CD123-directed cytotoxin for the treatment of the specific cancer
• This medication is administered to adult patients and pediatric patients 2 years and older with this type of cancer

Dosing Considerations

• Before initiating treatment of ELZONRIS, guarantee that the serum albumin is greater than or equal to 3.2 g/dL
• Patients with H1- histamine antagonist, H2- histamine antagonist, corticosteroids, and acetaminophen should be premedicated about 1 hour before initiating the ELZONRIS dose
• The patients should be monitored after the first cycle of administration in an in person setting for up to 24 hours after initiation of the last infusion
• The following cycles should be administered in an inpatient setting as well, or in a setting containing the equipment needed to treat and monitor the patients hematopoietic malignancies. Patients should be monitored for 4 hours following the previous infusion.

Preparation of ELZONRIS

Before initiating dosage, make sure the following components are available to provide the patient treatment safely and successfully: 1 empty 10 mL sterile vial, 0.9% of sodium chloride injection, 3 10 mL sterile syringes, 1 mini-bifuse Y-connector, microbore tubing, and 1 0.2 micron polyethersulfone in-line filter Elzonris should be thawed in a room with the temperature ranging from 15°C and 25°C (59°F and 77°F), for 15-30 minutes in its original container and carton. The thawed medication is permitted to be exposed to room temperature for 1 hour prior to dosage preparation. THE VIAL SHOULD NOT BE REFROZEN AFTER IT HAS BEEN THAWED. The presentation of thawed Elzonris should be clear and colorless liquid that might consist of a few white to translucent particles. Preparation should be done using aseptic techniques. The steps of preparation are as follows: Prepare 10 mL of 100 mcg/mL Elzonris:

• Use the sterile 10 mL syringe to transfer 9 mL of 0.9% sodium chloride injection,
• Gently swirl the vial to make sure all the contents have been mixed properly. Then, remove the cap from the vial to use the sterile 1 mL syringe to 1 mL of the thawed Elzonris
• Then transfer the 1 mL of Elzonris to the 10-mL vial that contains the sodium chloride injection. To mix the contents, slowly flip it back and forth. The final concentration is 100 mdg/mL.

Prepare the Elzonris infusion set to initiate treatment

• Calculate the weight-based required volume of the patient for the required volume of the diluted Elzonris (100 mcg/mL)
• Repeat all of step one if the required weight-based dosage is above 10 mL of diluted ELZONRIS (100 mcg/mL).
• Fill the syringes with at least 3 mL of the 0.9% sodium chloride injection. This will be used to flush the administration set after the dose has been administered to the patient.
• Connect the saline flush syringe to an arm of the Y-connecter (see above for required materials). Make sure the clamp is close, and then connect the product syringe to the other arm of the Y-connecter. Finally, connect the final end of the Y-connecter to the microbore tube.
• Use the supply side of the 0.2 micron filter and put it to the side.
• Now, unclamp the arm of the Y-connector that contains the product syringe, and prepare the entire infusion set. Cap the filter and reclamp the Y-connector line on the product side.

Administration of ELZONRIS

• The recommended dose for patients is 12 mcg/kg that is administered intravenously for a period of 15 minutes daily once. The medication should be administered on days 1 and 5 of a 21-day cycle.
• Patients should continue the treatment until the disease progresses, stops, or the patient suffers from unacceptable toxicity

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding ELZONRIS Off-Label Guideline-Supported Use and Dosage (Adult) in the drug label.

Non–Guideline-Supported Use

There is limited information regarding ELZONRIS Off-Label Non-Guideline-Supported Use and Dosage (Adult) in the drug label.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding ELZONRIS FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding ELZONRIS Off-Label Guideline-Supported Use and Dosage (Pediatric) in the drug label.

Non–Guideline-Supported Use

There is limited information regarding ELZONRIS Off-Label Non-Guideline-Supported Use and Dosage (Pediatric) in the drug label.

Contraindications

• There are no contraindications for administration of Elzonris.

Warnings

WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete Boxed Warning. There have been fatal and life-threatening cases of Capillary Leak Syndrome Before initiating treatment, check patient to ensure proper cardiac function and that serum albumin is greater than 3.2 g/dL Measure Albumin levels periodically during treatment, and monitor closely after ending treatment for a period of time that is clinically instructed Additionally, assess patients periodically and monitor carefully for signs or symptoms of CLS. Some signs and symptoms include weight gain, edema (new or progressively deteriorating), pulmonary edema, hypotension, orhemodynamic instability

Capillary Leak Syndrome

• In the Clinical Trial of 94 patients, the total reported incidence cases for Capillary Leak Syndrome is 55% or 52/94 patients. Patients that experienced Grade 1 or 2 CLS was 46%, Grade 3 6%, and Grade 4 1%. There were two reported deaths (2%).
• Some signs and symptoms that occur in patients treated with Elzonris include hypoalbuminemia, edema, weight gain, and hypotension
• Patients should be tested before initiating treatment to check for proper cardiac function and make sure the serum albumin is greater than or equal to 3.2 g/dL.
• Additionally, assess patients periodically and monitor carefully for signs or symptoms of CLS. Some signs and symptoms include weight gain, edema (new or progressively deteriorating), pulmonary edema, hypotension, orhemodynamic instability

Hypersensitivity Reactions

• Patients may suffer severe hypersensitivity reactions while undergoing treatment with Elzonris. In Clinical Trials, there were 46% or 43/94 patients who suffered hypersensitivity reactions. About 10% or 9/94 of the patients suffered from Grade 3 hypersensitivity reactions.
• Some hypersensitivity reactions that were reported with the clinical trial include: rash, pruritus, stomatitis, and wheezing.
• Patients should be monitored carefully for manifestation of hypersensitivity reactions, and if any arise immediately discontinue Elzonris treatment and care for the specific reaction present.
• Patients should talk with their medical practitioner to understand the side effects of the medication, and when to reduce the dose or discontinue forever.

Hepatotoxicity

• Trials showed that elevated liver enzymes were related to Elzonris infusions.
• Clinical trials showed that about 88% or 83/94 patients showed an increase in liver enzymes. About 48% of the patients showed signs of Grade 1 or 2 elevation levels, 36% showed Grade 3 in elevation levels, and about 4% showed Grade 4 in elevation levels of liver enzymes.
• Patients liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be monitored regularly and prior to every infusion.
• Temporarily discontinue treatment and daily dosage if the levels of the enzymes rises to greater than 5 times the upper limit of the normal levels, and recommence treatment once the levels have gone back to normal. Patients should talk to their doctor if they have any concerns about the levels of their liver enzymes and/or if the enzyme levels are consistently above normal.

Monitoring Disease Manifestations after ALPELISIB Discontinuation

Infusion Reactions

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Tagraxofusp-erzs Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Alpelisib Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Tagraxofusp-erzs Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There are no available data on ALPELISIB use in pregnant women to inform a drugassociated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Tagraxofusp-erzs in women who are pregnant.

Labor and Delivery

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Nursing Mothers

Women should not breastfeed while undergoing treatment with this medication and for 1 week after the last dose.

Pediatric Use

The safety and efficacy of ALPELISIB for the treatment of PNH in pediatric patients have not been established.

Geriatic Use

There were 117 patients in Solar-1 Clinical Trial that were of age 65 or older, and of that 75 patients were of the age 75 and up. There was a higher percentage of cases of Grade 3 or 4 hyperglycemia (44%) in patients of the age 65 and older compared to the incidence in patients less than the age of 65 (32%). Studies did not show a significant gap in effectiveness of Piqray comparing patients less than 65 years, and patients greater than 65 years of age.

Gender

There is no FDA guidance on the use of ALPELISIB with respect to specific gender populations.

Race

There is no FDA guidance on the use of ALPELISIB with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of ALPELISIB in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of ALPELISIB in patients with hepatic impairment.

Females of Reproductive Potential and Males

FDA guidance suggests healthcare providers should advise and counsel all patients with reproductive potential that ALPELISIB may impair fertility.

Immunocompromised Patients

There is no FDA guidance one the use of ALPELISIB in patients who are immunocompromised.

Administration and Monitoring

Administration

• Elzonris is administered intrvenously

Monitoring

There is limited information regarding Tagraxofusp-erzs Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Tagraxofusp-erzs and IV administrations.

Overdosage

In cases of overdosage with Elzonris, patients showed a similar set of adverse reactions as indicated in Elzonris’s profile. These include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight gain. There are no established protocols to entail an Elzonris overdose. As in all cases of overdose with every drug, “Initiate general symptomatic and supportive measures in all cases” If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Tagrxofusp-erzs
Systematic (IUPAC) name
(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
Identifiers
CAS number	1217486-61-7
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	441.5 g/mol
Pharmacokinetic data
Bioavailability	intravenously
Metabolism	hydrolysis reactions and CYP3A4
Half life	8 to 9 hours
Excretion	39.0L/h
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral use

Mechanism of Action

• Phosphatidylinositol-3-kinase-a (PI3Ka) mediates cell proliferation as a result of the growth-factor tyrosine kinase pathway activation. PI3Ka’s subunit is mutated in some cancers that make it hyperactive and out of control. Alpelisib inhibits PI3Ka with the highest specificity for it.

Structure

There is limited information regarding ALPELISIB Structure in the drug label.

Pharmacodynamics

There is limited information regarding Tagraxofusp-erzs Pharmacodynamics in the drug label.

Pharmacokinetics

The mean area under of the plasma plasma drug concentration over time curve 231 hr times mcg/liter and the maximum plasma concentration 162 mcg/L, resulting from the administration of Elzonris with a dose of 12 mcg/kg via 15-min infusion in patients.

Distribution

• The mean volume of distribution is 5.1 (1.9) L

Elimination

• 36% of Alpelisib is eliminated as the unchanged drug and 32% as the primary metabolite BZG791 through feces. These are for oral doses.
• 2% of the oral dose for Alpelisib is eliminated as the unchanged drug and 7.1% as the primary metabolite through urine
• 81% of an oral dose is eliminated in the faces and 14% in the urine

Specific Populations

• Advise patients to not breastfeed while undergoing treatment with Alpelisib and 1 week after the administration of the last dose

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

• Studies of carcinogenicity and mutagenicity have not yet been performed

Clinical Studies

Study SOLAR-1 (NCT02437318)

How Supplied

• Elzonris is supplied as an injection that is preservative free, sterile, clear, and colorless.
• It is a 1000 mcg in mL solution. It is supplied in a single-dose glass vial. Each of the cartons that it comes in contains one vial.

Storage

Elzonris should be stored in a freezer under temperatures ranging from -25°C and -15°C (-13°F and 5°F). Elzonris should be protected from the light, so leave it in its original packaging until its ready to be administered. The vials should be thawed at room temperature, 15°C and 25°C (59°F and 77°F), right before preparation. DO NOT REFREEZE THE VIAL AFTER IT HAS BEEN THAWED. Check the label for an expiration date, and do not use it beyond that date.

Images

Drug Images

{{#ask: Page Name::Tagraxofusp-erzs |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Tagraxofusp-erzs |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

Capillary Leak Syndrome

Hypersensitivity Reactions

Hepatotoxicity

Monitoring Disease Manifestations after ALPELISIB Discontinuation

Infusion Reactions

Discontinuation

• Patients will be advised to temporarily or permanently discontinue the medication if adverse reactions become severe or persist.

Infusion reactions

• Advise patients that administration of ALPELISIB may result in infusion reactions.

Precautions with Alcohol

Alcohol-Tagraxofusp-erzs interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

ELZONRIS

Look-Alike Drug Names

There is limited information regarding ALPELISIB Look-Alike Drug Names in the drug label.

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.